Univax regulatory update

The company said the letter raised no clinical issues that weren't discussed in detail at the Blood Products Advisory Committee panel in March, nor does the letter request additional clinical studies. According to UNVX, the letter requests additional background information on the completed clinical trials along with minor manufacturing questions. ...